Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 13,084 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Knee

NCT00733902
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
82
States / cities
Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Atlanta, Georgia • Detroit, Michigan • Cleveland, Ohio + 2 more
Conditions
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions
[212Pb]Pb-MP0712, [203Pb]Pb-MP0712
Drug · Other
Lead sponsor
Molecular Partners AG
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 14 more
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Conditions
Wilms Tumor
Interventions
Topotecan, Filgrastim (G-CSF), Pegfilgrastim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Memphis, Tennessee + 1 more
Completed Phase 3 Interventional Results available

Low-Dose Atropine for Treatment of Myopia

NCT03334253
Conditions
Myopia
Interventions
Atropine, Placebo Eyedrops
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boise, Idaho + 10 more
Conditions
Chronic Hepatitis C Infection, Genotype 1
Interventions
recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • National City, California • Miami, Florida + 3 more
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions
Surgery, Preoperative chemotherapy
Procedure · Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 45 more
Conditions
Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
Interventions
Avutometinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 30 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
arsenic trioxide
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
8
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 4 more
Conditions
Multiple Myeloma
Interventions
MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
34
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 27 more
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults

NCT01410305
Conditions
Vitamin D Deficiency
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
8 Years to 25 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions
Orbital Atherectomy, Balloon
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Conditions
GERD With Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Conditions
Heart Failure
Interventions
FDC I/H
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
19
States / cities
Tuscaloosa, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more
Conditions
Acute Myocardial Infarction
Interventions
Tenecteplase, Sterile Saline
Drug
Lead sponsor
C. Michael Gibson, MS, MD
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Gainesville, Florida • Atlanta, Georgia • Decatur, Georgia + 4 more
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
258
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more
Completed No phase listed Observational

Plegridy Observational Program

NCT02230969
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
50
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Conditions
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions
Local laboratory testing, Local Lab Tests
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more